Published in Int J STD AIDS on September 01, 2003
Factors mediating HIV risk among female sex workers in Europe: a systematic review and ecological analysis. BMJ Open (2013) 1.07
A qualitative exploration of barriers to condom use among female sex workers in China. PLoS One (2012) 0.94
Chlamydia trachomatis in female sex workers in Belgium: 1998-2003. Sex Transm Infect (2005) 0.88
Chlamydia trachomatis prevalence in undocumented migrants undergoing voluntary termination of pregnancy: a prospective cohort study. BMC Public Health (2008) 0.85
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis (2012) 3.49
Imported Chikungunya Infection, Italy. Emerg Infect Dis (2007) 2.08
Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis (2011) 1.97
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients. Clin Infect Dis (2008) 1.82
Natural history of chronic hepatitis B in co-infected patients. J Hepatol (2005) 1.77
Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol (2003) 1.75
Acute respiratory distress syndrome in Plasmodium vivax malaria in traveler returning from Venezuela. J Travel Med (2006) 1.71
Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther (2004) 1.65
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology (2011) 1.57
High attrition before and after ART initiation among youth (15-24 years of age) enrolled in HIV care. AIDS (2014) 1.48
High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine (2011) 1.43
Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. J Antimicrob Chemother (2009) 1.43
Schistosomiasis Screening of Travelers from Italy with Possible Exposure in Corsica, France. Emerg Infect Dis (2015) 1.42
Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. Antimicrob Agents Chemother (2009) 1.40
Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier García-Samaniego. HIV Clin Trials (2002) 1.37
Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol (2008) 1.36
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin (2004) 1.30
Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr (2003) 1.28
Factors predicting uptake of voluntary counselling and testing in a real-life setting in a mother-and-child center in Ouagadougou, Burkina Faso. Trop Med Int Health (2006) 1.25
Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) (2009) 1.24
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res (2007) 1.23
Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. Clin Infect Dis (2008) 1.23
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology (2010) 1.21
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology (2012) 1.20
Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis (2010) 1.18
Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev (2002) 1.18
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis (2003) 1.13
Therapy of uncomplicated falciparum malaria in Europe: MALTHER - a prospective observational multicentre study. Malar J (2012) 1.10
Increasing clinical virulence in two decades of the Italian HIV epidemic. PLoS Pathog (2009) 1.10
Knowledge, attitudes, and practices on malaria preventive measures of migrants attending a public health clinic in northern Italy. J Travel Med (2002) 1.10
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group. New Microbiol (2012) 1.10
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr (2011) 1.09
QuantiFERON-TB Gold test in the identification of latent tuberculosis infection in immigrants. J Infect (2007) 1.09
Trends in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA "search and isolate" strategy in a hospital in Italy with hyperendemic MRSA. Infect Control Hosp Epidemiol (2005) 1.07
Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PLoS One (2012) 1.06
Consensus document on controversial issues in the diagnosis and treatment of prosthetic joint infections. Int J Infect Dis (2010) 1.05
Methicillin-resistant Staphylococcus aureus ST398, Italy. Emerg Infect Dis (2010) 1.04
Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa. Infect Genet Evol (2005) 1.03
Fatal disseminated toxoplasmosis during primary HIV infection. Curr HIV Res (2007) 1.02
Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr (2003) 1.01
Congenital Plasmodium vivax malaria mimicking neonatal sepsis: a case report. Malar J (2010) 1.01
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis (2005) 0.99
Linezolid for the treatment of central nervous system infections in neurosurgical patients. Scand J Infect Dis (2002) 0.99
Schistosomiasis Screening of Travelers to Corsica, France. Emerg Infect Dis (2016) 0.98
An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol (2003) 0.97
HIV-related liver disease: ARV drugs, coinfection, and other risk factors. J Int Assoc Physicians AIDS Care (Chic) (2009) 0.95
Maternal characteristics during pregnancy and risk factors for positive HIV RNA at delivery: a single-cohort observational study (Brescia, Northern Italy). BMC Public Health (2011) 0.95
Cat-to-human orthopoxvirus transmission, northeastern Italy. Emerg Infect Dis (2009) 0.93
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol (2012) 0.93
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther (2008) 0.93
Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: the role of genotype 3. Curr HIV Res (2010) 0.93
Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. HIV Clin Trials (2002) 0.92
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antivir Ther (2010) 0.92
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol (2011) 0.91
Treating hepatitis C virus in HIV patients: are side effects a real obstacle? AIDS Rev (2007) 0.89
Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J Antimicrob Chemother (2005) 0.88
The burden of HIV and hepatitis C virus coinfection. Curr Opin HIV AIDS (2007) 0.88
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine. Curr Med Res Opin (2004) 0.86
Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr (2007) 0.86
Vaginal colonization with Candida spp. in human immunodeficiency virus-infected women: a cohort study. Int J STD AIDS (2006) 0.86
Predictors of AIDS-defining events among advanced naïve patients after HAART. HIV Clin Trials (2007) 0.86
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. J Clin Lab Anal (2002) 0.86
Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysis. J Med Virol (2008) 0.86
Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antivir Ther (2008) 0.86
Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART). Viral Immunol (2004) 0.85
Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther (2005) 0.85
Screening and Management of HIV-2-Infected Individuals in Northern Italy. AIDS Patient Care STDS (2008) 0.84
Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a. AIDS (2008) 0.84
Rhodococcus equi: pulmonary cavitation lesion in patient infected with HIV cured by levofloxacin and rifampicin. AIDS (2002) 0.84
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy. Antivir Ther (2006) 0.84
No evidence of benefical effect of GB virus type C infection on the course of HIV infection. AIDS (2002) 0.84
Exposure to polychlorinated biphenyls in residents near a chemical factory in Italy: the food chain as main source of contamination. Chemosphere (2006) 0.83
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. Drug Saf (2007) 0.83
HIV infection among illegal migrants, Italy, 2004-2007. Emerg Infect Dis (2009) 0.83
Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. J Antimicrob Chemother (2012) 0.83
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study. AIDS Patient Care STDS (2008) 0.83
Assessment of reference values for polychlorinated biphenyl concentration in human blood. Chemosphere (2005) 0.83
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. Antivir Ther (2008) 0.83
Mefloquine versus quinine plus sulphalene-pyrimethamine (metakelfin) for treatment of uncomplicated imported falciparum malaria acquired in Africa. Antimicrob Agents Chemother (2005) 0.83
Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. J Hepatol (2005) 0.83
African trypanosomiasis gambiense, Italy. Emerg Infect Dis (2005) 0.83
Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: is this a moving target? Intervirology (2004) 0.82
Emergence of exhausted B cells in asymptomatic HIV-1-infected patients naïve for HAART is related to reduced immune surveillance. Clin Dev Immunol (2012) 0.82
Adherence to hand hygiene in an Italian long-term care facility. Am J Infect Control (2008) 0.82
The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions. J Acquir Immune Defic Syndr (2009) 0.82
Tickborne encephalitis virus, northeastern Italy. Emerg Infect Dis (2006) 0.81